Arcus Biosciences (RCUS) EBIAT (2017 - 2025)
Arcus Biosciences (RCUS) has 9 years of EBIAT data on record, last reported at -$106.0 million in Q4 2025.
- For Q4 2025, EBIAT changed N/A year-over-year to -$106.0 million; the TTM value through Dec 2025 reached -$310.0 million, changed N/A, while the annual FY2025 figure was -$353.0 million, 24.73% down from the prior year.
- EBIAT reached -$106.0 million in Q4 2025 per RCUS's latest filing, up from -$112.0 million in the prior quarter.
- Across five years, EBIAT topped out at $279.4 million in Q4 2021 and bottomed at -$112.0 million in Q1 2025.
- Average EBIAT over 5 years is -$54.6 million, with a median of -$75.0 million recorded in 2023.
- The widest YoY moves for EBIAT: up 637.3% in 2021, down 4379.64% in 2021.
- A 5-year view of EBIAT shows it stood at $279.4 million in 2021, then crashed by 123.98% to -$67.0 million in 2022, then decreased by 20.9% to -$81.0 million in 2023, then dropped by 13.58% to -$92.0 million in 2024, then dropped by 15.22% to -$106.0 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$106.0 million in Q4 2025, -$112.0 million in Q1 2025, and -$92.0 million in Q3 2024.